David Baran

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6106549/publications.pdf

Version: 2024-02-01

91712 172207 5,113 124 29 69 citations h-index g-index papers 125 125 125 4982 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Venoarterial extracorporeal membrane oxygenation is a viable option as a bridge to heart transplant. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 140-147.e4.	0.4	8
2	Commentary: COVID-19 extracorporeal membrane oxygenation: A long way from home. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 1083-1084.	0.4	0
3	Variability in reporting of key outcome predictors in acute myocardial infarction cardiogenic shock trials. Catheterization and Cardiovascular Interventions, 2022, 99, 19-26.	0.7	21
4	Laboratory Markers of Acidosis and Mortality in Cardiogenic Shock: Developing a Definition of Hemometabolic Shock. Shock, 2022, 57, 31-40.	1.0	27
5	Influence of intraâ€aortic balloon pump on mortality as a function of cardiogenic shock severity. Catheterization and Cardiovascular Interventions, 2022, 99, 293-304.	0.7	14
6	A persistent problemâ€"The dreaded LVAD driveline infection. Journal of Cardiac Surgery, 2022, 37, 105-106.	0.3	4
7	Predicting the future: Hepatitis C donors in focus. Journal of Heart and Lung Transplantation, 2022, 41, 48-49.	0.3	0
8	SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies. Journal of the American College of Cardiology, 2022, 79, 933-946.	1.2	214
9	Heart Transplant Donor Selection: Recent Insights. Current Transplantation Reports, 2022, 9, 12.	0.9	0
10	SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies., 2022, 1, 100008.		8
11	Reply. JACC: Heart Failure, 2022, 10, 145.	1.9	0
12	The Multicenter Collaborative to Enhance Biologic Understanding, Quality, and Outcomes in Cardiogenic Shock (VANQUISH Shock): Rationale and Design. Canadian Journal of Cardiology, 2022, 38, 1286-1295.	0.8	6
13	Temporary mechanical circulatory support: Devices, outcomes, and future directions. Journal of Heart and Lung Transplantation, 2022, 41, 678-691.	0.3	9
14	OUP accepted manuscript. European Heart Journal: Acute Cardiovascular Care, 2022, , .	0.4	0
15	SCAI Position Statement on Best Practices for Percutaneous Axillary Arterial Access and Training. , 2022, 1, 100041.		2
16	Protocol-based anticoagulation management for mechanical circulatory support patients can be safe and efficient. International Journal of Artificial Organs, 2022, , 039139882210930.	0.7	0
17	Defining Shock and Preshock for Mortality Risk Stratification in Cardiac Intensive Care Unit Patients. Circulation: Heart Failure, 2021, 14, e007678.	1.6	38
18	Unraveling the Causes of Primary Graft Dysfunction. Transplantation, 2021, Publish Ahead of Print, .	0.5	0

#	Article	IF	CITATIONS
19	Commentary: In Search of the "Good Candidate―for Mechanical Circulatory Support. Journal of Thoracic and Cardiovascular Surgery, 2021, , .	0.4	O
20	Clinical outcomes of older adults listed for heart transplantation in the <scp>United States</scp> . Journal of the American Geriatrics Society, 2021, 69, 2507-2517.	1.3	12
21	How to Save a Life: Ex Vivo Heart Preservation. ASAIO Journal, 2021, 67, 869-870.	0.9	3
22	Pop the balloon: rapid switch from Intraâ€aortic balloon pump to alternate device. Clinical Case Reports (discontinued), 2021, 9, e04614.	0.2	1
23	A deceptively simple problem: the case of cardiogenic shock. European Journal of Heart Failure, 2021, 23, 1952-1954.	2.9	1
24	Intoxicated Donors and Heart Transplant Outcomes: Long-Term Safety. Circulation: Heart Failure, 2021, 14, e007433.	1.6	12
25	Lingua Franca of Cardiogenic Shock: Speaking the Same Language. Frontiers in Cardiovascular Medicine, 2021, 8, 691232.	1.1	1
26	Comparison of risk prediction models in infarct-related cardiogenic shock. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 890-897.	0.4	11
27	Better Together: A Reappraisal of Heterotopic Heart Transplantation. Transplant International, 2021, 34, 2184-2191.	0.8	2
28	Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop. Lancet Respiratory Medicine, the, 2021, 9, 1192-1202.	5.2	28
29	Gastrointestinal Bleeding Rates in Left Ventricular Assist Device Population Reduced with Octreotide Utilization. ASAIO Journal, 2021, 67, 989-994.	0.9	6
30	Post Heart Transplantation Outcomes of Patients Supported on Biventricular Mechanical Support. ASAIO Journal, 2021, Publish Ahead of Print, .	0.9	1
31	Everything I Wanted. JACC: Heart Failure, 2021, 9, 858-859.	1.9	0
32	Better Is the Enemy of Good: Ever-changing Heart Transplant Allocation. Transplantation Direct, 2021, 7, e645.	0.8	0
33	Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias. American Journal of Medicine, 2020, 133, 857-864.	0.6	8
34	Admission Society for Cardiovascular Angiography and Intervention shock stage stratifies post-discharge mortality risk in cardiac intensive care unit patients. American Heart Journal, 2020, 219, 37-46.	1.2	48
35	What Is the Role of Medical Therapy in Cardiogenic Shock in the Era of Mechanical Circulatory Support?. Canadian Journal of Cardiology, 2020, 36, 151-153.	0.8	5
36	Age and shock severity predict mortality in cardiac intensive care unit patients with and without heart failure. ESC Heart Failure, 2020, 7, 3971-3982.	1.4	25

#	Article	IF	CITATIONS
37	<scp>SCAI</scp> shock classification in acute myocardial infarction: Insights from the National Cardiogenic Shock Initiative. Catheterization and Cardiovascular Interventions, 2020, 96, 1137-1142.	0.7	68
38	The Stages of CS: Clinical and Translational Update. Current Heart Failure Reports, 2020, 17, 333-340.	1.3	10
39	Efficacy of Manual Hemostasis for Percutaneous Axillary Artery Intra-Aortic Balloon Pump Removal. Journal of Interventional Cardiology, 2020, 2020, 1-4.	0.5	3
40	Prospective validation of the <scp>SCAI</scp> shock classification: Single center analysis. Catheterization and Cardiovascular Interventions, 2020, 96, 1339-1347.	0.7	62
41	Systemic Inflammatory Response Syndrome Is Associated With Increased Mortality Across the Spectrum of Shock Severity in Cardiac Intensive Care Patients. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006956.	0.9	51
42	Percutaneous axillary access: A call to arms. Catheterization and Cardiovascular Interventions, 2020, 96, 1489-1490.	0.7	1
43	Influence of cardiac arrest and SCAI shock stage on cardiac intensive care unit mortality. Catheterization and Cardiovascular Interventions, 2020, 96, 1350-1359.	0.7	62
44	Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations. Journal of Heart and Lung Transplantation, 2020, 39, 1050-1069.	0.3	13
45	Differential gene expression in nonâ€adherent heart transplant survivors: Implications for regulatory Tâ€cell expression. Clinical Transplantation, 2020, 34, e13834.	0.8	0
46	Rejection: the emperor's new clothes. Transplant International, 2020, 33, 500-502.	0.8	0
47	Does pediatric heart transplant survival differÂwith variousÂcardiac preservation solutions?. Clinical Transplantation, 2020, 34, e14122.	0.8	6
48	Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines. Transplant International, 2019, 32, 1268-1276.	0.8	44
49	What Number Are We?. Circulation: Heart Failure, 2019, 12, e005823.	1.6	12
50	Cardiogenic Shock Classification toÂPredict Mortality in the CardiacÂIntensiveÂCare Unit. Journal of the American College of Cardiology, 2019, 74, 2117-2128.	1.2	314
51	SCAI clinical expert consensus statement on the classification of cardiogenic shock. Catheterization and Cardiovascular Interventions, 2019, 94, 29-37.	0.7	657
52	The Effect of Cardiac Preservation Solutions on Heart Transplant Survival. Journal of Surgical Research, 2019, 242, 157-165.	0.8	14
53	Early immune biomarkers and intermediate-term outcomes after heart transplantation: Results of Clinical Trials in Organ Transplantation-18. American Journal of Transplantation, 2019, 19, 1518-1528.	2.6	11
54	Pregnancy after heart transplant: not for the faint of heart. Transplant International, 2018, 31, 970-971.	0.8	1

#	Article	IF	CITATIONS
55	Differential responses to larger volume intraâ€aortic balloon counterpulsation: Hemodynamic and clinical outcomes. Catheterization and Cardiovascular Interventions, 2018, 92, 703-710.	0.7	19
56	A quality framework for the role of invasive, nonâ€interventional cardiologists in the presentâ€day cardiac catheterization laboratory: A multidisciplinary SCAI/HFSA expert consensus statement. Catheterization and Cardiovascular Interventions, 2018, 92, 1356-1364.	0.7	2
57	Corticosteroid Weaning in Stable Heart Transplant Patients: Guidance by Serum Cortisol Level. Journal of Transplantation, 2018, 2018, 1-6.	0.3	5
58	Outcomes with the Tandem Protek Duo Dual-Lumen Percutaneous Right Ventricular Assist Device. ASAIO Journal, 2018, 64, 570-572.	0.9	106
59	Late-onset right heart failure after left ventricular assist device implant: quo vadis?. Journal of Heart and Lung Transplantation, 2017, 36, 26-27.	0.3	9
60	A single center tertiary care experience utilizing the large volume mega 50cc intraâ€aortic balloon counterpulsation in contemporary clinical practice. Catheterization and Cardiovascular Interventions, 2017, 90, E63-E72.	0.7	11
61	Shedding Light on Cardiac Allograft Vasculopathy. JACC: Cardiovascular Imaging, 2017, 10, 785-786.	2.3	4
62	Impact of Left-Ventricular Assist Device–Related Complications on Posttransplant Graft Survival. Annals of Thoracic Surgery, 2017, 104, 1947-1952.	0.7	13
63	The Effect of Continuous-Flow Left Ventricular Assist Device Duration on Postoperative Outcomes. Annals of Thoracic Surgery, 2017, 104, 1933-1938.	0.7	6
64	Extracorporeal Membrane Oxygenation (ECMO) and the Critical Cardiac Patient. Current Transplantation Reports, 2017, 4, 218-225.	0.9	40
65	Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study. American Journal of Transplantation, 2016, 16, 121-136.	2.6	56
66	Acute left ventricular dysfunction complicating pregnancy on ECMO: Tri-iodothyronine to the rescue with real time transesophageal echocardiography. Journal of Cardiology Cases, 2016, 13, 33-36.	0.2	2
67	HEART AND LUNG FAILURE, TRANSPLANTOLOGY Meeting Update: International Society for Heart and Lung Transplantation 2014. Kardiochirurgia I Torakochirurgia Polska, 2015, 1, 37-41.	0.1	O
68	A Unique Case of Rituximab-Related Posterior Reversible Encephalopathy Syndrome in a Heart Transplant Recipient With Posttransplant Lymphoproliferative Disorder. American Journal of Transplantation, 2015, 15, 823-826.	2.6	10
69	Gene expression profiling to study racial differences after heart transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 970-977.	0.3	21
70	Pre-operative Speckle-tracking Imaging to Predict the Need for Right Ventricular Support in Patients Undergoing Left Ventricular Assist Device Implantation. Journal of Cardiovascular Disease Research (discontinued), 2015, 6, 1-11.	0.1	2
71	Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients With Ongoing Cardiogenic Shock. Critical Care Medicine, 2014, 42, 281-288.	0.4	25
72	Management of the ACC/AHA Stage D Patient. Cardiology Clinics, 2014, 32, 113-124.	0.9	10

#	Article	IF	CITATIONS
73	Orthotopic Heart Transplantation in Patients With Persistent Left Superior Vena Cava: Bicaval and Biatrial Techniques. Annals of Thoracic Surgery, 2014, 97, 1085-1087.	0.7	12
74	The courage to push: Donors and recipients. Journal of Heart and Lung Transplantation, 2014, 33, 139-140.	0.3	2
75	Utility of Gene Expression Profiling Score Variability to Predict Clinical Events in Heart Transplant Recipients. Transplantation, 2014, 97, 708-714.	0.5	34
76	Severe systemic vasospasm causing recurrent cardiac arrest after orthotopic heart transplantation. Journal of Heart and Lung Transplantation, 2013, 32, 1271-1272.	0.3	3
77	New directions in immunosuppression after heart transplantation. Nature Reviews Cardiology, 2013, 10, 422-427.	6.1	6
78	Relationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2013, 6, 216-223.	1.4	39
79	Left ventricular hypertrophy by electrocardiography and echocardiography in the African American Study of Kidney Disease Cohort Study. Journal of the American Society of Hypertension, 2012, 6, 193-200.	2.3	7
80	A Prospective, Randomized Trial of Single-Drug Versus Dual-Drug Immunosuppression in Heart Transplantation. Circulation: Heart Failure, 2011, 4, 129-137.	1.6	62
81	A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patients. EuroIntervention, 2011, 6, 949-954.	1.4	16
82	Immunosuppression and Heart Transplantation: How Do We Define Success?. American Journal of Transplantation, 2010, 10, 205-206.	2.6	4
83	Response:. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 910-910.	0.5	0
84	Response:. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 910-910.	0.5	0
85	Gene-Expression Profiling for Rejection Surveillance after Cardiac Transplantation. New England Journal of Medicine, 2010, 362, 1890-1900.	13.9	452
86	Cardiac transplantation and/or mechanical circulatory support device placement using heparin anti-coagulation in the presence of acute heparin-induced thrombocytopenia. Journal of Heart and Lung Transplantation, 2010, 29, 53-60.	0.3	31
87	The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. Journal of Heart and Lung Transplantation, 2010, 29, 914-956.	0.3	1,385
88	Epidemiology and Outcomes of Clostridial Bacteremia at a Tertiary-Care Institution. Scientific World Journal, The, 2009, 9, 144-148.	0.8	29
89	Simple Method to Eliminate Interference between Ventricular Assist Devices and Cardiac Rhythm Devices. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1142-1145.	0.5	20
90	A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology, 2008, 48, 49-52.	0.9	51

#	Article	IF	Citations
91	Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. European Heart Journal, 2007, 28, 1109-1116.	1.0	93
92	Statin Therapy Associated With a Reduced Risk of Chronic Renal Failure After Cardiac Transplantation. Journal of Heart and Lung Transplantation, 2007, 26, 264-272.	0.3	26
93	Randomized Trial of Tacrolimus Monotherapy: Tacrolimus In Combination, Tacrolimus Alone Compared (The TICTAC Trial). Journal of Heart and Lung Transplantation, 2007, 26, 992-997.	0.3	28
94	Induction Therapy in Cardiac Transplantation: When and Why?. Heart Failure Clinics, 2007, 3, 31-41.	1.0	15
95	The Role of Serial Testing for Heparin/PF4 Antibodies in Evolving HITT: A Unique Phenomenon of Delayed Seroconversion with Thrombosis Blood, 2007, 110, 1309-1309.	0.6	0
96	Long-term Results of Tacrolimus Monotherapy in Cardiac Transplant Recipients. Journal of Heart and Lung Transplantation, 2006, 25, 699-706.	0.3	28
97	Is Toxoplasmosis Prophylaxis Necessary in Cardiac Transplantation? Long-term Follow-up at Two Transplant Centers. Journal of Heart and Lung Transplantation, 2006, 25, 1380-1382.	0.3	37
98	Improved Survival With Statins, Angiotensin Receptor Blockers, and Steroid Weaning After Heart Transplantation. Transplantation Proceedings, 2006, 38, 1501-1506.	0.3	12
99	Lack of Sensitization and Equivalent Post-transplant Outcomes With the Novacor Left Ventricular Assist Device. Journal of Heart and Lung Transplantation, 2005, 24, 1886-1890.	0.3	20
100	De Novo Immunosuppression With Sirolimus and Tacrolimus in Heart Transplant Recipients Compared With Cyclosporine and Mycophenolate Mofetil: A One-Year Follow-Up Analysis. Transplantation Proceedings, 2005, 37, 2231-2239.	0.3	20
101	Safety and feasibility trial of the MicroMed DeBakey ventricular assist device as a bridge to transplantation. Journal of the American College of Cardiology, 2005, 45, 962-963.	1.2	37
102	Effects of Active vs. Passive Recovery on Work Performed During Serial Supramaximal Exercise Tests. International Journal of Sports Medicine, 2004, 25, 109-114.	0.8	54
103	Calcineurin Inhibitor-Associated Early Renal Insufficiency in Cardiac Transplant Recipients. American Journal of Cardiovascular Drugs, 2004, 4, 21-29.	1.0	36
104	Can initial tacrolimus trough levels be predicted from clinical variables?. Transplantation Proceedings, 2004, 36, 2816-2818.	0.3	3
105	Case report: A 32-year-old woman with familial parangangliomas and acute cardiomyopathy. Transplantation Proceedings, 2004, 36, 2819-2822.	0.3	8
106	Mycobacterium xenopi infection after heart transplantation: An unreported pathogen. Transplantation Proceedings, 2004, 36, 2834-2836.	0.3	9
107	Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. Transplantation Proceedings, 2004, 36, 3164-3166.	0.3	41
108	Cardiac transplantation in the older recipient: excellent long-term survival based on pretransplant screening. Transplantation Proceedings, 2003, 35, 2465-2467.	0.3	12

#	Article	IF	CITATIONS
109	Recent improvements in outcome with the novacor left ventricular assist device. Journal of Heart and Lung Transplantation, 2003, 22, 674-680.	0.3	44
110	"One size fits all": immunosuppression in cardiac transplantation. Annals of Transplantation, 2003, 8, 7-9.	0.5	4
111	Current practices: immunosuppression induction, maintenance, and rejection regimens in contemporary post-heart transplant patient treatment. Current Opinion in Cardiology, 2002, 17, 165-170.	0.8	14
112	Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. Transplantation, 2002, 74, 1136-1141.	0.5	26
113	A novel tacrolimus dosing strategy in cardiac transplantation: drug levels, renal function, and biopsy results. Transplantation Proceedings, 2002, 34, 1834-1835.	0.3	6
114	Tacrolimus and cardiac transplantation:. Transplantation Proceedings, 2002, 34, 1845-1846.	0.3	7
115	Predictors of early renal insufficiency in cardiac transplant recipients initiated on tacrolimus. Transplantation Proceedings, 2002, 34, 1872-1873.	0.3	8
116	Tacrolimus and new onset diabetes mellitus: the effect of steroid weaning. Transplantation Proceedings, 2002, 34, 1711-1712.	0.3	9
117	Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results. Journal of Heart and Lung Transplantation, 2001, 20, 59-70.	0.3	41
118	Validating Facemask Use for Gas Exchange Analysis in Patients With Congestive Heart Failure. Journal of Cardiopulmonary Rehabilitation and Prevention, 2001, 21, 94-100.	0.5	4
119	Effects of ??-Blockers on Neurohormonal Activation in Patients with Congestive Heart Failure. Drugs, 2000, 60, 997-1016.	4.9	16
120	AN IMMUNOLOGICALLY-GUIDED APPROACH SAFELY REDUCES BIOPSY FREQUENCY IN CARDIAC TRANSPLANTATION. Transplantation, 1999, 67, S567.	0.5	0
121	Renal function following infusion of radiologic contrast material. A prospective controlled study. Archives of Internal Medicine, 1985, 145, 87-89.	4.3	17
122	Describing and Classifying Shock: Recent Insights. US Cardiology Review, 0, 15, .	0.5	0
123	Functional status of heart transplant recipients predicts survival. Clinical Transplantation, 0, , .	0.8	3
124	Cardiac donors with renal impairment: Usage and outcomes after heart transplant. Clinical Transplantation, 0, , .	0.8	0